|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
reverse transcriptase inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:1995
gptkb:United_States
|
|
gptkbp:can_be_used_with
|
gptkb:abacavir
gptkb:efavirenz
gptkb:tenofovir
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:class
|
nucleoside analog
|
|
gptkbp:clinical_trial
|
Phase III
approximately 86%
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to lamivudine
|
|
gptkbp:developed_by
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:discovered_by
|
gptkb:Dr._David_Ho
|
|
gptkbp:duration
|
long-term therapy
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
fixed-dose combination
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lamivudine
|
|
gptkbp:ingredients
|
C8 H11 N3 O3 S
|
|
gptkbp:interacts_with
|
gptkb:didanosine
gptkb:stavudine
gptkb:zidovudine
|
|
gptkbp:invention
|
gptkb:2011
|
|
gptkbp:is_atype_of
|
J05 A F05
|
|
gptkbp:is_used_for
|
treatment of HIV
treatment of hepatitis B
|
|
gptkbp:lifespan
|
5 to 7 hours
|
|
gptkbp:marketed_as
|
gptkb:3_TC
gptkb:Epivir
|
|
gptkbp:name
|
essential medicines
|
|
gptkbp:pharmacokinetics
|
linear pharmacokinetics
|
|
gptkbp:previous_name
|
gptkb:battle
|
|
gptkbp:provides_information_on
|
WHO guidelines
CDC guidelines
|
|
gptkbp:reproduction
|
excreted in breast milk
|
|
gptkbp:safety_features
|
Category C (US)
|
|
gptkbp:shelf_life
|
2 to 3 years
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:traded_on
|
gptkb:3_TC
gptkb:Epivir
|
|
gptkbp:type_of
|
134678-17-4
|
|
gptkbp:water_resistance
|
HIV mutations
hepatitis B mutations
|
|
gptkbp:year_created
|
gptkb:1989
|
|
gptkbp:bfsParent
|
gptkb:Burroughs_Wellcome
|
|
gptkbp:bfsLayer
|
4
|